Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 16Colonic Neoplasms 11Rectal Neoplasms 8Head and Neck Neoplasms 7Neoplasm Metastasis 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Chordoma 2Breast Neoplasms 2Unresectable Colorectal Cancer 1Tongue Neoplasms 1Thymoma 1Solid Tumor, Adult 1Solid Cancer 1Skin Neoplasms 1Rectal Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Noonan Syndrome 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1

Interventions

Gemcitabine 7Cisplatin 6durvalumab 5pembrolizumab 4gemcitabine-oxaliplatin regimen 3S 1 (combination) 3Carboplatin 3Trastuzumab 2Paclitaxel 2Capecitabine 2tucatinib 1tremelimumab 1merestinib 1irinotecan sucrosofate 1envafolimab 1Tegafur 1Ramucirumab 1Radiation 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Itraconazole 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Fulvestrant 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Biliary Tract Neoplasms × Cetuximab × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡